PTJ
VIRX

Paul Tudor Jones’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Paul Tudor Jones’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-83
Closed -$45K – 1649
2014
Q4 		$45K Buy
+83
New +$37.4K ﹤0.01% 1400

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Paul Tudor Jones's VIRX Position: Q1 2015 in Review

Paul Tudor Jones sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2015, closing a stake of 83 shares — an estimated $45K sold.

Paul Tudor Jones first reported a position in VIRX in Q4 2014 and held it in 1 quarter. The position peaked at $45K in Q4 2014. 83 funds tracked by Wall St. Rank hold VIRX as of Q1 2015.

  • Paul Tudor Jones reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Paul Tudor Jones sold 83 Viracta Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $45K.
  • Paul Tudor Jones first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 1 quarter.
  • Paul Tudor Jones's Viracta Therapeutics, Inc. Common Stock position peaked at $45K in Q4 2014.
  • 83 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Tudor Investment Corp's 13F filing for Q1 2015, filed 15 May 2015.